Literature DB >> 7926081

Angiotensin II immunoreactivity is elevated in ascites during severe ovarian hyperstimulation syndrome: implications for pathophysiology and clinical management.

A Delbaere1, P J Bergmann, C Gervy-Decoster, M Staroukine, Y Englert.   

Abstract

OBJECTIVE: To investigate the ovarian renin-angiotensin system (RAS) during severe ovarian hyperstimulation syndrome (OHSS).
DESIGN: Simultaneous sampling of blood and ascitic or peritoneal fluid (PF) during therapeutic paracentesis or laparoscopy.
SETTING: University Hospital. PATIENTS: Twelve patients were investigated: three patients presenting severe OHSS, three patients with a spontaneous first trimester pregnancy, three normally cycling women during the early luteal phase, and three patients with ascites of nonovarian origin. MAIN OUTCOME MEASURE: Renin-like activity and angiotensin II (ANG II) immunoreactivity were measured simultaneously in the plasma and the ascites or PF.
RESULTS: Angiotensin II immunoreactivity was much higher in the ascites or PF than in corresponding plasma during severe OHSS, first trimester pregnancy, and in the early luteal phase, while it was lower in ascites of nonovarian origin. Renin-like activity and ANG II immunoreactivity were the highest in the ascites of severe OHSS and in the PF from part of the patients with a spontaneous first trimester pregnancy.
CONCLUSIONS: The present findings argue for the ovarian origin of the elevated renin-like activity and ANG II immunoreactivity in the ascites of severe OHSS and suggest a stimulatory role of hCG on the ovarian RAS whether during severe OHSS or first trimester spontaneous pregnancy. The vasoactive peptide ANG II may contribute to the maintenance of the ascites in severe OHSS but is probably not responsible for the formation of the ascites. The efficiency of paracentesis during severe OHSS could be explained at least partially by the removing of great amounts of ANG II from the peritoneal cavity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7926081     DOI: 10.1016/s0015-0282(16)56997-0

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  10 in total

Review 1.  Understanding ovarian hyperstimulation syndrome.

Authors:  Anne Delbaere; Guillaume Smits; Anne De Leener; Sabine Costagliola; Gilbert Vassart
Journal:  Endocrine       Date:  2005-04       Impact factor: 3.633

2.  What is the best predictor of severe ovarian hyperstimulation syndrome in IVF? A cohort study.

Authors:  Theoni B Tarlatzi; Christos A Venetis; Fabienne Devreker; Yvon Englert; Anne Delbaere
Journal:  J Assist Reprod Genet       Date:  2017-07-14       Impact factor: 3.412

Review 3.  The pathogenesis of ovarian hyperstimulation syndrome: a continuing enigma.

Authors:  A Simon; A Revel; A Hurwitz; N Laufer
Journal:  J Assist Reprod Genet       Date:  1998-04       Impact factor: 3.412

4.  Spontaneous Late Onset OHSS in Singleton Pregnancy in 2nd Trimester: A Rare Case.

Authors:  Hampanagouda N Patil; Rajib Roy; Raja Pal; Joydeb Roychowdhury
Journal:  J Obstet Gynaecol India       Date:  2014-09-26

5.  Features of the Renin-angiotensin system in ascites and pleural effusion during severe ovarian hyperstimulation syndrome.

Authors:  A Delbaere; P J Bergmann; Y Englert
Journal:  J Assist Reprod Genet       Date:  1997-05       Impact factor: 3.412

Review 6.  Safety of drugs used in assisted reproduction techniques.

Authors:  Talha Al-Shawaf; Ariel Zosmer; Martha Dirnfeld; Gedis Grudzinskas
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

7.  A rise of the serum level of von Willebrand factor occurs before clinical manifestation of the severe form of ovarian hyperstimulation syndrome.

Authors:  S Ogawa; H Minakami; S Araki; T Ohno; M Motoyama; H Shibahara; I Sato
Journal:  J Assist Reprod Genet       Date:  2001-02       Impact factor: 3.412

8.  THE ROLE OF HIGH FOLLICULAR LEVELS OF ANGIOTENSIN II AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN ANTICIPATING THE DEVELOPMENT OF SEVERE OVARIAN HYPERSTIMULATION SYNDROME IN PATIENTS WITH PROPHYLACTIC CABERGOLINE THERAPY UNDERGOING AN IN VITRO FERTILIZATION PROCEDURE.

Authors:  M Surcel; M Surcel; C Zlatescu-Marton; R Micu; G I Nemeti; D D Axente; C Mirza; I Neamtiu
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Jan-Mar       Impact factor: 0.877

9.  Successful outcome of severe ovarian hyperstimulation syndrome (OHSS) with 27 liters of ascitic fluid removed by paracentesis.

Authors:  D Grochowski; E Sola; M Kulikowski; W Kuczyński; S Wołczyński; M Szamatowicz
Journal:  J Assist Reprod Genet       Date:  1995-07       Impact factor: 3.412

Review 10.  New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome?

Authors:  A Delbaere; G Smits; O Olatunbosun; R Pierson; G Vassart; S Costagliola
Journal:  Hum Reprod       Date:  2004-01-29       Impact factor: 6.918

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.